nVerses Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

nVerses Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,900	Closed	-$285K	–	950
2024 Q3	$285K	Buy	+3,900	New	+$293K	0.13%	251

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

nVerses Capital's ITCI Position: Q4 2024 in Review

nVerses Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2024, closing a stake of 3,900 shares — an estimated $285K sold.

nVerses Capital first reported a position in ITCI in Q3 2024 and held it in 1 quarter. The position peaked at $285K in Q3 2024. 387 funds tracked by Wall St. Rank hold ITCI as of Q4 2024.

nVerses Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 3,900 Intra-Cellular Therapies Inc. shares in Q4 2024, an estimated $285K.
nVerses Capital first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 1 quarter.
nVerses Capital's Intra-Cellular Therapies Inc. position peaked at $285K in Q3 2024.
387 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.